Business

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Pegcetacoplan met the primary endpoint in the PEGASUS study, demonstrating superiority to eculizumab

articleApellis Pharmaceuticals, Inc.January 7, 20203/company/apellis-pharmaceuticals-inc/news/apellis-reports-positive-top-line-results-from-phase-3-head-to-head-study-of-pegcetacoplan-apl-2-compared-to-eculizumab-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-pnh

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

About this update from Apellis Pharmaceuticals, Inc.

[{"type":"text","content":"Pegcetacoplan met the primary endpoint in the PEGASUS study, demonstrating superiority to eculizumab (p","length":145,"tagName":"div"}]

More updates from Apellis Pharmaceuticals, Inc.